In order to promote the use of multigene panel testing of breast cancer patients, we need to understand the prevalence of germline mutations particularly in cancer predisposition genes beyond BRCA1/2 to identify the genes commonly mutated in our population. The gene discussed is BRCA1; the disease is breast cancer.